ALPINE
10 Nov 2020
ALPINE
NCT03734016
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphocytic Lymphoma
BeiGene
Cancer Type | Lymphoma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Lymphoma |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | - |
Anticipated End Date | - |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Stanley Cheung |
Recruitment Status | Recruiting |